CytomX Therapeutics, Inc. | Collaboration Agreements | Business Contracts

Amendment No 3 to Collaboration and License Agreement, dated May 23, 2014, by and between the Company and Bristol Myers Squibb Company, effective as of October 11, 2022 (Filed With SEC on November 8, 2022)

Amendment No. 2 to the Collaboration and License Agreement, dated as of October 27, 2021, by and between CytomX Therapeutics, Inc. and Amgen, Inc (Filed With SEC on March 1, 2022)

Amendment No 2 to Collaboration and License Agreement, as amended, dated March 17, 2017, by and between the Company and Bristol Myers Squibb, effective as of February 22, 2021 (Filed With SEC on May 6, 2021)

Research Collaboration, Option and License Agreement dated as of May 30, 2013, by and between CytomX Therapeutics, Inc. and Pfizer, Inc (Filed With SEC on November 5, 2020)

Collaboration and License Agreement dated as of May 23, 2014, by and between CytomX Therapeutics, Inc. and Bristol-Myers Squibb Company (Filed With SEC on November 5, 2020)

Amendment No. 1 to the Collaboration and License Agreement, dated as of September 29, 2020, by and between CytomX Therapeutics, Inc. and Amgen, Inc (Filed With SEC on November 5, 2020)

Collaboration and License Agreement dated as of March 23, 2020, by and between CytomX Therapeutics, Inc. and Astellas Pharma Inc (Filed With SEC on May 7, 2020)

Amended and Restated Discovery Collaboration and License Agreement, dated as of June 28, 2019, by and between CytomX Therapeutics, Inc., and AbbVie Ireland Unlimited Company (Filed With SEC on August 7, 2019)

CytomX Therapeutics, Inc. (38) | Collaboration Agreements (8)